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Abstract
Background: The use of alkylating agents such as temozolomide in association with radiotherapy (RT) is the
therapeutic standard of glioblastoma (GBM). This regimen modestly prolongs overall survival, also if, in light of
the still dismal prognosis, further improvements are desperately needed, especially in the patients with O6-
methylguanine-DNA-methyltransferase (MGMT) unmethylated tumors, in which the benefit of standard treatment
is less. Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor (AK-DACi) molecule that fuses
the DNA damaging effect of bendamustine with the fully functional pan-histone deacetylase (HDAC) inhibitor,
vorinostat, in a completely new chemical entity.
Methods: Tinostamustine has been tested in models of GBM by using 13 GBM cell lines and seven patient-derived
GBM proliferating/stem cell lines in vitro. U87MG and U251MG (MGMT negative), as well as T98G (MGMT positive),
were subcutaneously injected in nude mice, whereas luciferase positive U251MG cells and patient-derived GBM stem
cell line (CSCs-5) were evaluated the orthotopic intra-brain in vivo experiments.
Results: We demonstrated that tinostamustine possesses stronger antiproliferative and pro-apoptotic effects than
those observed for vorinostat and bendamustine alone and similar to their combination and irrespective of MGMT
expression. In addition, we observed a stronger radio-sensitization of single treatment and temozolomide used as
control due to reduced expression and increased time of disappearance of γH2AX indicative of reduced signal and
DNA repair. This was associated with higher caspase-3 activation and reduction of RT-mediated autophagy. In vivo,
tinostamustine increased time-to-progression (TTP) and this was additive/synergistic to RT. Tinostamustine had
significant therapeutic activity with suppression of tumor growth and prolongation of DFS (disease-free survival) and
OS (overall survival) in orthotopic intra-brain models that was superior to bendamustine, RT and temozolomide and
showing stronger radio sensitivity.
Conclusions: Our data suggest that tinostamustine deserves further investigation in patients with glioblastoma.
Keywords: Glioblastoma, Bendamustine, Vorinostat, Tinostamustine, Radio sensitivity
* Correspondence: claudio.festuccia@univaq.it
1Laboratory of Radiobiology, Department of Applied Clinical Sciences and
Biotechnologies, University of L’Aquila, L’Aquila, Italy
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Festuccia et al. Journal of Hematology & Oncology  (2018) 11:32 
https://doi.org/10.1186/s13045-018-0576-6
Background
High-grade gliomas are the most frequent and aggressive
primary brain tumor in the adults. Grade IV gliomas named
also glioblastoma (GBM) show a devastating clinical evolu-
tion, a short survival, and a poor quality of life. Currently,
therapeutic standards show 27 and 10% of survival when
considered the analyses at 2 and 5 years from diagnosis [1].
Although the benefits are modest and of limited duration,
temozolomide-based chemotherapy is part of the standard
treatment for GBM in the first-line and recurrent settings
[2]. Temozolomide is an alkylating agent that triggers DNA
damage [3]. Molecular pathways (direct DNA damage re-
versal, base excision repair [BER], and mismatch repair
[MMR]) are activated after alkylation DNA damage as
mechanisms of defense towards cell death or large muta-
tions. Temozolomide (TMZ) is a second-generation imida-
zotetrazine lipophilic prodrug that crosses the blood-brain
barrier (BBB) and induces GBM cell death by introducing
alkyl groups into DNA cross links [3]. This drug forms O6-
methylguanine, N3 methyl adenine, and N7 methylguanine
adducts leading to the formation of single- and double-
strand DNA breaks associated with both apoptosis and
senescence of tumor cells [4]. Temozolomide resistance
involves, indeed, both O6-methylguanine-DNA-methyl-
transferase (MGMT)-dependent and MGMT-independent
mechanisms. MGMT protects the cellular genome from the
mutagenic effects of TMZ by removing the O6-
alkylguanine DNA adducts [5], thereby reducing the effect
of TMZ. MGMT promoter methylation status is responsible
for regulating MGMT expression and has been statistically
significantly correlated with increased survival in GBM pa-
tients receiving the standard treatment (49 versus 15%, 2-
year survival rate) [5, 6]. The MMR system is critical for the
maintenance of replication fidelity and for inducing appro-
priate cellular responses to DNA damage [4]. In mismatch
repair, MMR-deficient cells may become tolerant to the
mispairing of O6-methylguanine with thymine. N3 methyl
adenine and N7 methylguanine may be repaired by BER
enzymes including MPG, 3-methylpurine-DNA glycosylase.
Maximal safe surgical resection followed by RT with con-
comitant TMZ administration indicates that patients have a
post-operative expected survival of 12–15 months [1, 6].
Tumor recurrence is mediated by the recruitment of glioma
stem-like cells named also as tumor-initiating cells (TIC).
This event is often associated also with resistance to stand-
ard therapies [7, 8].
Bendamustine (BDM) is an alkylating chemothera-
peutic agent displaying a unique pattern of cytotoxicity
compared with TMZ [9]. This is a bifunctional
mechlorethamine derivative with properties similar to
those seen with cyclophosphamide, chlorambucil, and
melphalan, containing a purine-like benzimidazole ring
similar to cladribine. This molecule was designed to
have both alkylating and anti-metabolite properties.
Differences with other alkylating agents have been
observed in regard to its effects on DNA repair and cell
cycle progression. Moreover, BDM can induce cell
death through both apoptotic and non-apoptotic path-
ways, thereby retaining activity even in cells without a
functional apoptotic pathway. BDN appears to have
only a partial cross resistance to other alkylating agents
[9–11] and was used as a salvage therapy monotherapy
for recurrent GBM [12]. Histone deacetylases (HDAC)
are frequently overexpressed in tumors including
GBMs [13] and control the gene expression, cell prolif-
eration, and drug resistance of tumor cells [14].
Recently, we observed that high-intensity HDAC4 and/
or HDAC6 immunostaining was predictive of poor clin-
ical outcome in patients with GBM treated with stand-
ard chemo-radiotherapy [13]. In vitro experiments
demonstrated also that silencing of HDAC4 or HDAC6
was able to radio-sensitize resistant U87MG and
U251MG GBM cell lines through the promotion of
DNA double-strand break (DSB) accumulation and
down-modulation of DSB repair molecular machinery
activity. HDAC inhibitors (HDACi) represent anti-
cancer drugs that alter both the epigenome (and this is
the gene expression) and the function of crucial non-
histone protein. It has been widely demonstrated that
administration of HDACi modulates the differentiation
status [14–17] of glioma cells through modification of
expression levels of differentiation or stemness proteins
[14] as for example GFAP, β-catenin, or nestin. The de-
tection of these proteins together to stem cell markers
(CD133, CD44, and Sox2) may help to discriminate gli-
oma cells to glioma stem-like cells [16, 17]. They also
exert a synergistic effect with, or additive to, other anti-
cancer treatments, including RT [18, 19]. While vorinostat
(suberoylanilide hydroxamic acid, SAHA) and panobino-
stat have undergone equal evaluation as combination ther-
apies for TMZ in glioblastoma [20, 21], of the potential
for HDACi may be as a radio-sensitizer inducing chroma-
tin relaxation, altering transcription of DNA damage
repair genes and common cell death pathway synergisms
[22]. Furthermore, despite increasing the efficacy of
chemotherapeutic agents such as TMZ [22, 23], HDAC
inhibitors may potentiate the evolution of acquired TMZ
resistance linked to MGMT upregulation in glioblastoma
xenografts [24]. Tinostamustine (EDO-S101; TINO) is the
first-in-class alkylating deacetylase inhibitor (AK-DACi)
molecule which was designed to create a very potent cyto-
toxic agent for systemic use, with the aim of increasing
the efficacy of the alkylating DNA damage through
deacetylase-mediated chromatin relaxation. In TINO, the
active structures of SAHA and BDM were fused together
to create a completely new chemical entity. Preclinical ex-
periments and biochemical characteristics are shown in
references [25–27] and demonstrated that TINO exerts
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significant activity against several hematological malignan-
cies. In addition, the molecule is active in primary resist-
ant cells as well as in cells that have acquired resistance
[26].
The aim of this study is to investigate the antitumor
effects of TINO in association with radiotherapy in
preclinical models and to compare activity with standard
of care.
Methods
Reagents and drugs preparation
Plasticware and materials for tissue culture were purchased
from Euroclone (EuroClone S.p.A, Milan, Italy). Antibodies
for β-actin [sc-130065], acetylated-histone H3 (Lys 24) [sc-
34262], and total histone H3 (Ser 28) [sc-24516], GFAP
(2E1) [sc-33673], nestin [sc-23927], β-catenin [sc-7199],
LC3-II [sc-271625], beclin1 [sc-48341], and p62 [sc-28359]
were purchased from Santa Cruz (Santa Cruz, CA, USA).
Survivin antibody was purchased from Biorbyt (Cambridge,
UK). Antibodies against E-cadherin and MIB1 (Ki67) were
purchased from Dako (Carpenteria, CA). We used the
ApopTag® peroxidase in situ apoptosis detection kit pur-
chased from Merck Millipore (Merck, Milan, Italy). Vessel
count was detected by using anti-mouse CD34 from
eBioscience, Inc. (Prodotti Gianni SpA, Milan Italy). Bend-
amustine HCl, TMZ, and vorinostat (SAHA) were pur-
chased from Selleckchem (Aurogene, Rome Italy).
Tinostamustine (TINO) was provided by Mundipharma-
EDO GmbH. For in vitro cell viability assays, TINO was
dissolved in dimethyl sulfoxide (DMSO) and used at final
concentrations of < 0.5% DMSO. For in vivo test, TINO
was prepared as an intravenous injection solution contain-
ing 15% HPBCD, 1.5% acetic acid, and 1.25% NaHCO3.
Since TINO undergoes hydrolysis in aqueous solution, it is
very important to immediately dose the animals after each
fresh formulation is made.
AT101, a small Bcl2 inhibition molecule, was kindly
provided from Jeffrey M. Brill (Ascenta Therapeutics, Inc.,
Malvern, PA). AT101 was dissolved in DMSO to obtain a
stock solution of 100 mM. and used at 5 μM in culture.
Cell lines
Twelve human glioma cell lines (U251MG, U373, U118,
U138, A172, U87MG, LN19, SW1783, SNB19, LN229,
T98G, and D54) were cultured at 37 °C in 5% CO2 and
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% (v/v) fetal bovine serum, 4 mM
glutamine, 100 IU/ml penicillin, 100 μg/ml streptomycin,
and 1% nonessential amino acid (Thermo Fisher/Life
Technologies, Inc., Carlsbad, CA, USA). To minimize the
risk of working with misidentified and/or contaminated cell
lines, we stocked the cells used in this report at very low
passages and used < 20 subcultures. Periodically, a DNA
profiling by GenePrint® 10 System (Promega Corporation,
Madison, WI) was carried out to authenticate cell cultures.
Karyotypically distinct U251MG, SNB19, and U373 cell
lines were defined to be the same origin but have different
drug treatment sensitivities. Similarly, U138-MG cells show
strong similarity to U118-MG cells, sharing at least six de-
rivative marker chromosomes. Luciferase-transfected
U87MG cells were kindly provided by Jari E. Heikkila,
Department of Biochemistry and Pharmacy, Abo Akademi
University, Turku, Finland. Six GBM patient-derived stem
cell lines (BT12M, BT25M, BT48EF, BT50EF, BT53M),
kindly provided by J. Gregory Cairncross and Samuel Weiss
(Hotchkiss Brain Institute, Faculty of Medicine, University
of Calgary, Calgary, Alberta, Canada) [28] and GSCs-5 and
CSCs-7 [29] from Marta Izquierdo (Departamento de
Biología Molecular, Universidad Autónoma de Madrid,
Spain) were maintained as neurosphere cultures in Neuro-
cult medium (Stem Cell Technologies, Vancouver, BC,
Canada) supplemented with epidermal growth factor
(20 ng/ml) and fibroblast growth factor (10 ng/ml). GSCs-5
cells were transfected with pGL4.13 vector (Promega Italia,
Milan) using jetPEI (Polyplus) to create a stable luciferase
expression clone selected by limited dilution.
Cell viability assay
The cytotoxicity of TINO, BDM, and TMZ was measured
by the Cell Counting Kit-8 (CCK-8; Dojindo Molecular
Technologies Inc., Tokyo, Japan) as suggested by its pro-
ducer. The optical density (OD) values were averaged and
normalized against the controls to generate dose-response
curves to calculate the IC50 values using Grafit software.
Cell cycle and apoptosis analysis
SubG1 cell percentage (resulting in a mixture of necro-
sis, autophagy, and apoptosis) was detected with Propi-
dium Iodide (PI) by using Tali™ instrument (Thermo
Fisher Scientifics, Carlsbad, CA, USA). Apoptosis was
analyzed using Alexa Fluor® 488 Annexin V/Dead Cell
Apoptosis Kit (Life Technologies Europe BV, Monza,
Italy). All cells were then measured on a Tali® Image-
Based Cytometer measuring the fluorescence emission
at 530 nm (e.g., FL1) and > 575 nm. The results were
expressed as the percentage of cell death by apoptosis in
controls and in treated cultures.
HDAC activity assay
HDAC activity was evaluated by a colorimetric HDAC
activity assay kit (Enzo Life Sciences GmbH) in nuclear
extracts of cells treated as previously described [30].
Clonogenic survival assay
For clonogenic survival, exponentially growing cells
(70% confluence) were cultured in regular media and
treated with TINO, at the appropriate concentrations, or
vehicle (final DMSO concentration of 0.1%) for 24 h.
Festuccia et al. Journal of Hematology & Oncology  (2018) 11:32 Page 3 of 19
Tumor cells were then irradiated at room temperature
with increasing doses of radiation (0–6 Gy) using an X-
ray linear accelerator (dose rate of 200 cGy/min). Non-
irradiated controls were handled identically to the irradi-
ated cells, with the exception of the radiation exposure.
After treatment, cells were diluted at the appropriate
concentration (1000 cells) and re-seeded into a new 100-
mm tissue culture dish (in triplicate) and incubated for
14 days. At day 14, the media was removed and colonies
were fixed with methanol:acetic acid (10:1, v/v) and
stained with crystal violet. Colonies containing > 50 cells
were counted. The plating efficiency (PE) was calculated
as the number of colonies observed/the number of cells
plated; the surviving fraction (SF) was calculated as fol-
lows: colonies counted/cells seeded X (PE/100). The
mean inactivation dose was calculated according to the
method of Fertil [31], and the cell survival enhancement
ratio (ER) was calculated as the ratio of the mean inacti-
vation dose under controlled conditions, divided by the
mean inactivation dose after drug exposure, as described
by Morgan [32]. We also used the “dose enhancement
factor” as the ratio between “dose with radiation alone
and dose with radiation + drug”. A value significantly > 1
indicates radio-sensitization.
Comet assay
The comet assay was carried out by using the OxiSelect™
96-well Comet Assay Kit (Cell Biolabs Inc., San Diego
CA) and measured as suggested by its producer. Analyses
were performed in triplicate and presented data represent
mean ± standard error (SE) and consider three replicated
experiments.
AVO staining
AVO staining was used to detect the presence of acidic
vesicles after treatments. Cells were treated with a final
concentration of 1 μM of acridine orange solution at 37 °
C for 15 min, washed in phosphate-buffered saline (PBS),
and observed under a fluorescence microscope (excitation
= 488 nm, emission = 520 nm) (Carl Zeiss, Germany).
Western blotting
Following treatments, cells, grown in 90 mm diameter
Petri dishes, were washed with cold PBS and immedi-
ately lysed with 1 ml lysis buffer containing a proteinase
and phosphatase inhibitor cocktail. Total lysates were
electrophoresed in 7% SDS-PAGE, and separated pro-
teins were transferred to nitrocellulose and probed with
the appropriate antibodies using the conditions recom-
mended by the suppliers. Total extracts were normalized
by using an anti-β-actin antibody.
ELISA determinations
After appropriate treatments, floating and adherent cells
(obtained from the medium and a PBS wash, or after trypsi-
nization, respectively) were pooled and pelleted by centrifu-
gation. Cell pellets were washed with PBS, lysed with RIPA
buffer, and assayed by ELISA determinations for (i) active
human Caspase-3 (CBA045, Merck Chemicals Ltd. Not-
tingham, UK), Beclin-1 protein expression (E98557Hu,
USCN life sciences, Houston, TX, USA) and DNA damage
assay (EpiQuik in situ DNA Damage Assay Kit; Epigentek,
Farmingdale, NY, USA). All experiments were performed
following the manufacturer’s protocols. Analyses were per-
formed in triplicate and presented data represent mean ±
standard error (SE) and consider three replicated experi-
ments. APOSTRAND™ ELISA apoptosis detection kit (code
BML-AK120-0001) and p62 ELISA kit (code ADI-900-212-
0001) were purchased from Enzo Life Sciences, Inc.
(Farmingdale, NY, USA). Beclin 1 ELISA (code SEJ557Hu)
was purchased from 2BScientific (Heyford Park, UK).
Human MAP1LC3B / LC3B ELISA Kit was purchased
from LifeSpan BioSciences (Seattle, WA, USA).
Mouse glioblastoma xenograft model
Female CD1-nu/nu mice, at 6 weeks of age, were pur-
chased from Charles River (Milan, Italy) under the
guidelines established by our Institution (University of
L’Aquila, Medical School and Science and Technology
School Board Regulations, complying with the Italian
government regulation no. 116 January 27, 1992 for the
use of laboratory animals). All mice received subcutane-
ous flank injections (two each) of 1 × 106 U251, U87MG
and T98G cells representing models for MGMT nega-
tive, MGMT gene methylated and MGMT positive cells.
Tumor growth was assessed bi-weekly by measuring
tumor diameters with a Vernier caliper. If we considered
a xenograft as equivalent to an ovoid having three diam-
eters: the formula used was ‘TW (mg) = tumor volume
(mm3) = 4/3πR1 × R2 × R3 in which R1/R2/R3 are the 1/
2 diameters (rays), shorter diameter is the thickness/
height of tumor, larger diameters are the length and
width of tumor [33–35]. At about 10 days after the
tumor injection, 30 mice with tumor volumes of 0.5~
0.8 cm3 were retained and randomly divided into six
groups (five mice per group with two tumors each)
named (1) control (vehicle), (2) TINO (60 mg/kg at days
1, 8, and 15 q28 days, iv), (3) radiotherapy (RT, 4 Gy de-
livered in a single fraction [34]), and (4) TINO plus RT.
These treatments were compared with standard therap-
ies consisting of TMZ and TMZ plus RT. Therefore, two
additional groups were included: (5) TMZ (16 mg/kg/5
consecutive days) and (6) TMZ plus RT. Anesthetized
tumor-bearing mice received a focal irradiation. All mice
were shielded with a specially designed lead apparatus to
allow irradiation to the right hind limb. Mice were kept
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under these conditions until all irradiation finished. At
the end of experiments (35 days after the start of treat-
ments), animals were sacrificed by carbon dioxide inhal-
ation and tumors were subsequently removed surgically.
Half of the tumor was directly frozen in liquid nitrogen
for protein analysis and the other half fixed in parafor-
maldehyde overnight for immunohistochemical analyses.
Indirect immunoperoxidase staining of tumor xenograft
samples was performed on paraffin-embedded tissue
sections (4 μm). Tumor microvessels were counted at ×
400 in five arbitrarily selected fields, and the data were
presented as number of CD34+ mouse microvessels/×
100 microscopic field for each group. Ki67 labeling index
was determined by counting 500 cells at 100× and deter-
mining the percentage of cells staining positively for
Ki67. Apoptosis was measured as the percentage of tun-
nel positive cells ±standard deviation (SD) measured on
five random fields (400×).
Evaluation of treatment response in vivo (xenograft
model)
The following parameters were used to quantify the anti-
tumor effects upon different treatments as previously
described [33, 34]: (1) tumor volume measured during
and at the end of experiments, (2) tumor weight mea-
sured at the end of experiment, (3) tumor progression
(TP or doubling time) defined as an increase of greater
than 100% of tumor volume with respect to baseline,
and (4) time to progression (TTP) defined as the time
for tumor progression.
Orthotopic intra-brain model
Female CD1 nu/nu mice were inoculated intra-cerebrally
as previously described [33, 34] with luciferase-transfected
U251 and patient-derived GBM stem cell line (GSCs-5).
Just before treatment initiation (5 days after injection), an-
imals were randomized to treatment groups of 10 mice
each. In vivo bioluminescence images were obtained using
the UVITEC Cambridge Mini HD6 (UVItec Limited,
Cambridge, UK). Animals were anesthetized, and luciferin
(150 mg/kg) was injected intra-peritoneally (IP) 15 min
prior to imaging. The mice were photographed while
placed on their front, and the bioluminescence intensity
(BLI) was measured in the region of interest. We deliber-
ately inoculated a small number of cells (3 × 103) to simu-
late a chemo-radio-therapeutic treatment made after
surgery in which a low number of tumor cells, remaining
the wound bed, and re-grow resulting in a recurrence.
Treatments were started 5 days after cell injection when
no luciferase activity was intracranially detectable. Mice
were euthanized when they displayed neurological signs
(e.g., altered gait, tremors/seizures, lethargy) or weight loss
of 20% or greater of pre-surgical weight.
Statistics
Continuous variables were summarized as mean and SD or
as median with 95% CI. For continuous variables not
normally distributed, statistical comparisons between
control and treated groups were established by carrying out
the Kruskal-Wallis tests. When Kruskal-Wallis tests
revealed a statistical difference, pair-wise comparisons were
made by Dwass-Steel-Chritchlow-Fligner method and the
probability of each presumed “non-difference” was indi-
cated. For continuous variables normally distributed, statis-
tical comparisons between control and treated groups were
established by carrying out the ANOVA test or by Student
t test for unpaired data (for two comparisons). When the
ANOVA revealed a statistical difference, pair-wise compari-
sons were made by Tukey’s HSD (honestly significant
difference) test and the probability of each presumed “non-
difference” was indicated. Dichotomous variables were
summarized by absolute and/or relative frequencies. For
dichotomous variables, statistical comparisons between
control and treated groups were established by carrying out
Fisher’s exact test. For multiple comparisons, the level of
significance was corrected by multiplying the P value by the
number of comparisons performed (n) according to Bonfer-
roni correction. TTP was analyzed by Kaplan-Meier curves
and Gehan’s generalized Wilcoxon test. When more than
two survival curves were compared, the log-rank test for
trend was used. This tests the probability that there is a
trend in survival scores across the groups. All tests were
two-sided and were determined by Monte Carlo signifi-
cance. P values < 0.05 were considered statistically signifi-
cant. SPSS® (statistical analysis software package) version
10.0 and StatDirect (version. 2.3.3., StatDirect Ltd) were
used for statistical analysis and graphic presentation.
Results
First, glioma cell models were grouped for MGMT ex-
pression levels. As previously described SF268, T98G,
U138, U118, LN18, D54, and SW1783 show high levels
of MGMT, whereas U251, U87, A172, U373, SNB19,
and LN229 show low or absent levels due to complete
or hemi-methylation of MGMT gene [36–39]. Seven
GBM patient-derived stem cell lines were characterized
as MGMT positive (BT12M, BT25M, BT50EF, and CSC-
7) and negative (BT48EF BT53M and CSCs-5) [39].
Antitumor effects of TINO in glioma cell models:
comparison with BDM and SAHA alone or in combination
Initially different concentrations of BDM and TMZ were
tested for inhibition of cell proliferation in our cell
cohort. In Fig. 1a, we show the representation of crystal
violet stain assay performed in U87MG cells. MTT was
used to calculate the inhibition concentration at 50%
(IC50) values. This assay was also used to compare the
effects of temozolomide (Fig. 1b), bendamustine (Fig. 1c),
Festuccia et al. Journal of Hematology & Oncology  (2018) 11:32 Page 5 of 19
and tinostamustine (Fig. 1d) in the different cell lines.
Bendamustine (BDM) showed IC50 values ranging be-
tween 5.5 and 65.3 μM. Conversely, the majority of the
cytotoxic effects caused by TMZ occurred between 12
and 334 μM. Interestingly, BDM was found to retain its
cytotoxic activity when tested both against MGMT
negative and TMZ-resistant cell lines (22.6 ± 10.9 μM
[mean ± SD] versus 36.4 ± 21.8 μM, respectively P =
0.0968 [NS]) In contrast, the effects of TMZ were
strongly dependent on MGMT expression (73.4 ±
20.1 μM in MGMT negative cells versus 190.7 ±
29.4 μM, in MGMT positive cells P = 0.0187). The ef-
fects of TINO were tested in the same cell systems:
Based on IC50 values, TINO was found to be amongst
the most potent agents tested with a range of 1.7 μM
and 52.0 μM (6.1 ± 1.3 μM in MGMT negative versus
13.3 ± 4.8 μM in MGMT positive, P = .1629 NS). All cell
lines, including 5/7 GSC lines resulted in a moderately/
highly sensitive IC50 ranged between 4.3 and 13.4 μM
and 2/7 GSC showed IC50 > 25 μM. These data suggest
a TINO IC50 of a 5 to 25 order of magnitude lower than
for BDM. The effects of TINO were compared with a
combination treatment using a fixed nontoxic dose of
SAHA (200 nM) and increasing concentrations of BDM
in U87MG, U251, A172, and T98G cell lines. The IC50
values decreased significantly in the four cell systems
suggesting that SAHA was a chemo-sensitizing com-







Fig. 1 Antitumor effects of TINO in glioma cell models: comparison with BDM and SAHA alone or in combination. a Representative crystal violet stain
assay performed in U87MG cells. b IC50 values for temozolomide (TMZ) in different glioma and stem-like cells. c IC50 values for Bendamustine (BDM) in
different glioma and stem-like cells. d IC50 values for tinostamustine (TINO) in different glioma and stem-like cells. In b, c, and d were added two markers:
a red line showing the pharmacologically active concentration measured at the blood peak in humans for temozolomide (35 μM) and bendamustine
(20 μM) as well as in brains of mice for tinostamustine (11.2 μM in the CNS after single i.v. bolus injection of 40 mg/kg, Huan Tun and collaborators
manuscript submitted) and a dashed blue line indicating the in vitro cell sensitivity/resistance to the drugs. e Comparison on BDM and combination
treatments using a fixed nontoxic dose of SAHA (200 nM) and increasing concentrations of BDM in U87MG, U251, A172, and T98G cell lines. f Histone
deacetylase activity: comparison of inhibitory effects of SAHA and TINO. Single results are representative of three different experiments performed
in triplicate
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HDAC activity assay that TINO maintained the HDAC in-
hibition activities of SAHA in the acetylation status of his-
tone H3 (Fig. 1f). Similar inhibition of H3 histone
deacetylation by SAHA and TINO was shown in U87MG
cells. Similarly, SAHA and TINO were able to modulate
differentiation status of U87MG cells, including the ex-
pression of MGMT. GFAP, nestin, and β-catenin proteins
were also similarly modulated by SAHA and TINO at
IC50 values (data not shown) suggesting that TINO main-
tained the differentiation properties of SAHA.
Tinostamustine increases the effects of radiotherapy in
glioma models in vitro
To determine the effects of TINO on the radio-
sensitivity of GBM cells, a clonogenic assay was
performed. As drug exposure times are longer during
clonogenic survival studies with radiation, 1 μM TINO
was considered. This value was lower than the IC20
value for the majority of GBM cell lines. The in vitro
analyses were performed on 4/12 high-grade glioma cell
lines (U87MG, U251, A172, and T98G) chosen as
models for molecular and functional studies. The choice
on these models resulted from the necessity to have sen-
sitivity scale versus RT and TINO administration. Treat-
ment of glioma cells with 1 μM TINO alone yielded a
surviving fraction of 0.90 ± 0.064 in U251, 0.77 ± 0.18 in
U87, 0.94 ± 0.036 in T98G, and 0.85 ± 0.12 in A172.
Tinostamustine induced a strong radio-sensitizing effect
in our cell models (Fig. 2a). In the combination protocol
24–48 h after drug administration, cells were irradiated
at 2, 4, and 6 Gy and colony forming efficiency was de-
termined 30 days later. Clonogenic assay (Fig. 2b) dem-
onstrates that this combination treatment resulted in a
dose enhancement factor (DRE) of 1.50 in U251, 1.55 in
U87MG, 1.38 in A172, and 1.68 in T98G cells. Next, we
evaluated the changes in apoptotic, autophagic, and
necrotic proteins in our four cell models. In agreement
with the previous data demonstrating that in glioma
cells, RT-associated cell death was mainly a mixture of
necrosis and autophagy [40], we show a dose-dependent
increase in cathepsin D cleavage and calpain 1 autolysis
(necrosis). Similarly, a dose-dependent increment of
levels of LC3B, for cleavage of LC3 protein, and beclin 1
associated with a decrement or loss of p62 protein were
observed (autophagy). In addition, we demonstrated that
the administration of TINO, administered at IC50 values
reduced LC3B and Beclin 1 levels as well as slowed/im-
peded the down-modulation of p62. In Fig. 2c, we show
western bots obtained in representative A172 cell ex-
tracts. Similar results were obtained in U87MG, U251,
and T98G cells. Next, p62 and beclin1 levels were quan-
tified by ELISA determinations performed in quintupli-
cate. Mean values (mean values ± standard errors, SD)
were transformed as % versus relative controls. These
results are shown in Fig. 2d. Comet assay were per-
formed on culture treated with different doses of RT
with or without 3.5 μM TINO. In Fig. 2e, we show rep-
resentative data obtained on A172 cells. We demon-
strated that the co-administration of TINO amplified
the DNA damage (comets) induced by RT. Similar re-
sults were obtained in U87MG, U251, and T98G. In
Fig. 2f, we quantified the comets as percentage of cells
with comets analyzed in our four cell models of glioma.
All together, these results were associated with a strong
increase of sub-G1 cell percentage obtained by FACS
(Fig. 3a). In Fig. 3b, we show that Bcl2 and Bax levels
were weakly upmodulated after RT treatment. TINO
was able to reduce Bcl2 and maintain high Bax expres-
sion when administered in combination with RT doses
suggesting a possible replacement of autophagy in this
combinatorial therapy. In agreement with these data, we
found that caspase 3 activity was significantly increased
after TINO administration (Fig. 3c). A further demon-
stration of Bcl2 in increased apoptosis was evident by
the comparison of the percentage of annexin V/PI-posi-
tive cells (apoptosis, Fig. 3d) versus the total subG1 cell
population (mixed cell death) in RT and RT + TINO
treatments. Next, we analyzed the role of Bcl2 in this
phenomenon by using the bcl2 inhibitor AT101 at dose
of 5.0 μM [41]. We observed that also AT101 showed in
glioma cell models strong radio-sensitizing effects in
agreement with our previous experiments [42]. In Fig. 3e,
we show the clonogenic curves for our four cell models.
The analyses of dose enhancement factor values (Fig. 3f )
showed, however, lower radio-sensitizing effects to those
observed for TINO. When AT101 was co-administered
with the combination TINO + RT, the clonogenic curves
showed a further dose enhancement factor as indicated
in Fig. 3g. This increase was, however, significantly low
due of high AT101 dose used for this triple pharmaco-
logical combination.
When combined with RT, TINO induced deep mor-
phological changes that were evident in GBM cell cul-
tures (Fig. 4a) (U251) and 4B (U87MG). In our
experiments with TINO and or RT, we find that the
morphology of U87MG passed from one messy appear-
ance of cell colony to an intermediated epithelial like/
fibroblastoid and bipolar nature morphology. In the old
version of figure, I had chosen a more dense control for
TINO administration to show the morphology change at
sub-confluence. A further demonstration of reduced ne-
crosis after administration of TINO to RT-treated cell
cultures was evident for T98G cells after staining with
acridine orange and propidium iodide (Fig. 4c). The
presence of orange/red stained cells due to the accumu-
lation of acidic vacuolar organelles (AVO) was elevated
with RT in a dose-dependent manner. The addition of
TINO reduced the presence of AVO in treated cells. The
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percentage of AVO-stained cells on five different 10×
stained microscopic field in U87MG, U251, and T98G
cells was associated with increased γH2Ax staining
(Fig. 4d). In Fig. 4e, T98G cultures stained for γH2Ax at
24 h after RT administration alone or combined with
TINO. In Fig. 4f, U87MG, U251, and T98G cell cultures
were treated with RT alone or in combination with
TINO and levels of γH2Ax were quantified by immuno-
enzymatic colorimetric assay. The levels of γH2Ax were
elevated in combined treatments after 24 h from start of
experiment. In agreement with literature data, RT ad-
ministration caused H2Ax phosphorylation, and γH2AX
levels were maximal within 4–6 h, reaching baseline
values within 12 h. Tinostamustine-induced maximal
γH2AX levels were observed within 2–4 h with a slower
decrease in the time and an achievement of baseline
values within 24–48 h. When TINO was combined with
RT, the levels of γH2AX were higher within 2–4 h and
the time necessary to reach baseline values of γH2AX
was slightly increased (data not shown) suggesting that
DNA repair was impaired (reduced or retarded).
Similar experiments were repeated by using the
patient-derived glioma stem cell cultures. Evaluation of
RT in combination with IC20 TINO (8 μM) in 4/7 gli-
oma stem-like (BT12M, BT48EF, BT53EF, and CSCs-5)
cells demonstrated a reduction in the number of col-
onies compared with RT alone (Fig. 5a, BT12M cell
model). Clonogenic curves were generated considering
the number of colonies made up at 21 days of cultures
and DRE calculated for our cell models and data shown
in Fig. 5b. DRE values were significantly higher com-






Fig. 2 Tinostamustine increases the effects of radiotherapy in glioma models in vitro (part I). a Clonogenic assay performed on U87MG, U251, A172, and
T98G cells showing radio-sensitizing effects of tinostamustine (TINO). b Comparison between dose enhancement factor (DRE) calculated in U87MG, U251,
A172, and T98G in cultures treated with Rt combined to SAHA, BDM, SAHA + BDM, and TINO and showing higher DRE values in the combination of TINO
and RT. c Western blots for autophagy and necrosis marker expression in A172 cells used as representative cell line for this analyses. d ELISA determination
of beclin 1 and p62 proteins in U87MG, U251, A172, and T98G cells. ELISA determinations performed in quintuplicate. Mean values (mean values ± stand-
ard errors, SD) were transformed as % versus relative controls. e Representative comet assay obtained in A172 cells treated with different doses of RT with
or without 3.5 μM TINO. f Quantification of comet assays as percentage of comets (with intermediated/high comet tails) in U87MG, U251, A172, and T98G;
Single results are representative of three different experiments performed in triplicate. Statistical analyses: *p< 0.005
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and ranged between 1.44 (BT50EF) and 1.70 (BT12M).
This was associated with increased apoptosis and a
lower contribution of necrosis as suggested by (i) west-
ern blot and ELISA determinations (Fig. 5c, 5d) showing
a reduction of RT-mediated expression of LC3B and
Beclin 1 and induction of p62), (ii) DNA ladder (Fig. 5e,
representative BT12M cells), (iii) BCl2 down-modulation
after tinostamustine administration (Fig. 5c), and (c) in-
creased caspase 3 activity (Fig. 5g for all four cell
models). Low contribution of autophagy in cell death
was also suggested analyzing the differences of percent-
age of sub-G1 cell distribution (Fig. 5f ) and annexin V/
PI positive (Fig. 5h) cells.
In vivo efficacy of TINO alone or in combination with RT
(subcutaneous xenograft model)
To assess the effect on tumors in an in vivo model, 1 ×
106 cells of U251, U87MG, and T98G GBM cells were
subcutaneously injected in female cd1 nu/nu mice. The
changes in tumor volumes were measured in order to
calculate the TTP. At the end of the therapy cycle (35–
50 days), animals were sacrificed and the tumor har-
vested, weighed, and processed for molecular and histo-
chemical analyses. Tinostamustine monotherapy
demonstrated an anti-tumor effect reducing tumor
weight by 40, 56, and 60% in U251 (Fig. 6a), U87MG
(Additional file 1: Figure S1A), and T98G (Fig. 6f ) xeno-
grafts, respectively. TINO also increased the antitumor
effects of RT reducing tumor weight by 82, 80, and 76%
(compared with vehicle) in U87MG, U251, and T98G
xenografts, respectively. Since RT alone reduced tumor
weight by 20, 22, and 33% in the same cell models, a
resultant combination index [CI] can be calculated for
each xenograft: 0.73 in U87MG, 0.97 in U251, and 0.87
in T98G. These CI values suggest additive/synergy be-
tween TINO and RT. Temozolomide showed efficacy
similar to TINO monotherapy in U87MG and U251








Fig. 3 Tinostamustine increases the effects of radiotherapy in glioma models in vitro (part II). a Table summarizing subG1 cell percentage measured with
propidium iodide (PI) by using Tali™ instrument (Thermo Fisher Scientifics, Carlsbad, CA, USA) in U87MG, U251, A172, and T98G treated with RT with or
without TINO. b Western blot performed on Bcl2 and Bax expression performed in A172 cells treated with RT (0–6 Gy) with or without TINO 3.5 μM. c
Caspase 3 activity measured in U87MG, U251, A172, and T98G treated with RT (0–6 Gy) with or without TINO. d Annexin V/PI positive apoptotic cells
performed by using Tali™ Apoptosis Kit - Annexin V Alexa Fluor™ 488 & Propidium Iodide. e Clonogenic assay performed with AT101 (Gossypol, 10.0 μM),
Bcl2 inhibitor in U87MG, U251, A172, and T98G. f Table summarizing DRE values calculated in U87MG, U251, A172, and T98G treated with RT (0–6 Gy) with
or without 10.0 μM AT101. g Table summarizing DRE values calculated in U87MG, U251, A172, and T98G treated with RT (0–6 Gy) with or without 10.0 μM
AT101 and TINO 3.5 μM (triple combination). Single results are representative of three different experiments performed in triplicate
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compared with controls, whereas a very low effect
(12% reduction versus control) was observed in T98G
cells. Temozolomide used at 16 mg/kg (equivalent hu-
man dose for mice [43]) also increased RT sensitivity,
with tumor weight reductions (compared with vehicle
control) of 83% (CI = 0.85), 71% (CI = 0.74), and 57%
(CI = 0.89), in U87MG, U251, and T98G, respectively.
CI values for TMZ were also in the range of syner-
gism. The TTP was plotted versus time to generate
Kaplan-Meier curves showed a significant antitumor
effect with TINO monotherapy (Fig. 6b, 6f and
Additional file 1: Figure S1B for U251, T98G, and
U87 cell xenografts, respectively) was superior to
those observed for RT and TMZ mono-therapies.
The combination with RT and TMZ or TINO showed
higher radio-sensitizing effects of TINO than TMZ
(Fig. 6c, g and Additional file 1: Figure S1C for U251,
T98G, and U87 cell xenografts, respectively). Tinosta-
mustine showed similar effects to the gold standard in
all cell models. However, a forest plot graphical repre-
sentation of this meta-analysis demonstrates greater ef-
fects (higher hazard ratios (HR)) with TINO than RT
and TMZ as single treatments. Similarly, TINO showed
greater RT sensitizing effects with higher HRs when
combined with RT compared with the RT plus TMZ
combination (Fig. 6c, 6d; Fig. 6h–6l; Additional file 1:
Figure S1C, D and E, in U251, T98G, and U87MG cell





Fig. 4 Morphological and functional effects of TINO when combined with RT in glioma cell lines. a Morphological changes observed in U251
cells after treatments with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μM. b Morphological changes observed in U87MG cells after
treatments with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μM. c Representative expression of acidic vacuolar organelle (AVO)
accumulation in T98G cells cultured with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μM. d Percentage of AVO-stained cells in
U87MG, U251, and T98G cells cultured with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μM. Statistical analysis: *p < 0.005 in the
comparison between combined TINO + RT treatment and RT alone. Single results are representative of three different experiments performed in
triplicate. e Immunocytochemical evaluation of γH2Ax stain in T98G cells cultured with 4, 6, and 8 Gy (RT) alone or in association with TINO
3.5 μM. f Quantization of γH2AX expression in U87MG, U251, and T98G cells treated with RT with or without TINO. Statistical analyses: *p < 0.005
in the comparison between RT + TINO and RT or TINO treatments alone. Single results are representative of three different experiments
performed in triplicate
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RT was more effective than the gold standard (RT plus
TMZ) in all cell xenografts with HR = 0.94, 2.35, and
3.39 in U251, U87MG, and T98G xenografts, respect-
ively, suggesting a higher effects in MGMT+/TMZ re-
sistant T98G cells. Additional file 2: Table S1
summarized the statistical analysis for the Kaplan-Meier
curves showed in Additional file 1: Figure S1 and Fig. 6.
Histopathological and immunohistochemical effects of
treatment with RT and/or tinostamustine
Histologically, U87MG, U251, and T98G tumors show
glial morphology associated to high tumor cell rate and
elevated cell pleomorphism. In Fig. 7a, we show this ap-
pearance for T98G. A narrow band of leukocyte infil-
trate, consisting of granulocytes, B lymphocytes, and
monocyte/macrophages may surround the tumors and
constitute a specialized neoplastic microenvironment
(T98G, Fig. 7b). Tumor cells are dispersed a fibrillar col-
lagen background that may envelop abundant vascula-
ture (Fig. 7c, 7d). A pseudopalisading necrosis was also
evident in addition to thrombotic vessels and
hemorrhage. Necrosis and fibrosis are increased in the
combination treatment with TINO and RT when com-
pared to tinostamustine administration or RT treatment
alone. In Fig. 7e, we show the analysis on necrosis (per-
centage or necrotic areas in 10 separate histological
fields in T98G tumors comparing our treatments with
the standard therapies (temozolomide and temozolo-
mide associated with RT). The percentage of necrotic
areas was significantly higher in TINO + RT treatment
compared to TINO and RT alone and similar to those
observed for the treatment with temozolomide and RT.
This was associated with reduced areas with high tumor
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Fig. 5 Effects of TINO with or without RT in patient derived glioma stem-like cells. a Effects of RT (0, 2, 4, and 6 Gy) with or without TINO in
BT12M cell model. b DRE values calculated for BT12M, BT48EF, BT50EF, and CSCs-5 patient-derived glioma stem-like cells. c, d Western blot and
ELISA determinations indicating the shift from authophagy to apoptosis. e DNA ladder in representative BT12M cells. f Table summarizing subG1
cell percentage measured with propidium iodide (PI) by using Tali™ instrument (Thermo Fisher Scientifics, Carlsbad, CA, USA) in BT12M, BT48EF,
BT50EF, and CSCs-5 patient-derived glioma stem-like cells. g Caspase 3 activity performed in BT12M, BT48EF, BT50EF, and CSCs-5 patient-derived
glioma stem-like cells. h Annexin V/PI-positive apoptotic cells performed by using Tali™ Apoptosis Kit - Annexin V Alexa Fluor™ 488 & Propidium
Iodide. Single results are representative of three different experiments performed in triplicate






Fig. 6 Radiosensitizing effects of TINO on tumor weight and time to progression in U251 and T98G xenograft models. a Analysis of tumor weights
harvested at the end of experiment (50th day from randomization) in U251MG xenografts. b Kaplan-Meier curves generated for time to progression in
U251: comparisons amongst RT, TMZ, and TINO single therapies. c Kaplan-Meier curves generated for time to progression: analysis of radio-sensitizing
effects of TINO for U251G xenografts in comparison with TMZ and RT + TMZ. d Forest plots (U251) for the comparison of TTP distribution in different
treatments with untreated animals (vehicle). e Forest plots (U251) for comparison of TTP in the different combination regimens. f Analysis of tumor
weights harvested at the end of experiment (35th day from randomization) in T98G xenografts. g Kaplan-Meier curves generated for time to
progression in T98G: comparisons amongst RT, TMZ, and TINO single therapies. h Kaplan-Meier curves generated for time to progression: analysis of
radio-sensitizing effects of TINO for T98G xenografts in comparison with TMZ and RT + TMZ. i Forest plots for the comparison of TTP distribution in
different treatments with untreated animals (vehicle). j Forest plots for comparison of TTP in the different combination regimens
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stroma (Fig. 7c, 7d). Elevated percentage of necrotic re-
gions could be due to an inadequate blood supply as a
response to treatment. So, the expression of VEGF was
evaluated in the blood of mice bearing T98G tumors
(Fig. 7d). Increased fibrosis and reduced angiogenesis are
related to reduced Ki67 as shown for U87MG xenograft
in Fig. 7g.
Orthotopic models: luciferase-transfected GBM cells
The efficacy of TINO was investigated in an orthotopic
mouse model using differentiated luciferase-transfected
GBM cells (U251). A small number of cells (3 × 103) were
inoculated deliberately to simulate treatment post-surgery.
Treatments were started 5 days after cell injection when no
luciferase activity was detectable intracranially; the animals
were treated for 35 days and followed for a maximum of
220 days. Disease-free survival (DFS, Fig. 7a) was the time
without brain bioluminescence, and overall survival (OS,
Fig. 7f) as the time necessary to observe clinical signs of
distress ethically considered for the sacrifice of animals. As
first analyses, we evaluated the recurrence time defined as
the time in which a luciferase activity was intracranially
detectable. Untreated animals showed bioluminescence sig-
nals after about 30 days (35.0 ± 2.7; mean ± SEM). RT in-
creased DFS, slowing mean recurrence to 40.0 ± 3.8 days
(Fig. 7a). Mean recurrence was also significantly slowed
with TINO (55.0 ± 6.3) and TMZ (115 ± 16.4) treatments.
Combination with RT further slowed time of recurrence by
120 ± 13.7 days for TINO and 105 ± 14.2 for TMZ. The
comparison between TINO + RT and TMZ+RT combina-
tions plus RT was not significant. Kaplan-Meier curves
demonstrated that TINO monotherapy reduced tumor pro-
gression compared with untreated animals (Figs. 7b and 8d)
with results superior to RT and TMZ alone though not sig-
nificantly greater than RT + TMZ. Statistically significant
differences in the radio-sensitizing effects of TINO versus
TMX were observed in this radio- and chemo-sensitive
model (Fig. 7c, 7e). In U251 orthotopic intra-brain xeno-
graft, untreated animals showed distress signs and were
sacrificed after about 50 days (55.0 ± 3.6). RT increased OS,
slowing mean recurrence to 70.0 ± 7.3 days. Mean recur-
rence was also significantly slowed with TINO (120.0 ±
11.6) and TMZ (120 ± 8.7) monotherapies. Combination
with RT further slowed time of recurrence to 180 ± 7.1 days
a b c d
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Fig. 7 Representative histopathological and immunohistochemical images in T98G tumors treated with TINO and TINO + RT. a, b Hematoxylin/eosin
staining for glial appearance of T98G tumors and leukocyte infiltrate. c Different pattern of fibrillar collagen scaffold with necrosis and fibrosis areas
evaluated by trichromic stain. d Modification of vascular architecture in TINO and RT + TINO treatments. e Determination of necrotic areas in T98G
tumors and comparison amongst experimental groups. f VEGF-A determination on plasma collected from mice bearing T98G tumors and comparison
amongst experimental group. g Ki67 staining (proliferating index) in T98G tumors harvested from different experimental group
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for TINO plus RT which was significantly greater than for
TMZ plus RT: 160 ± 4.8 for. Kaplan-Meier curves showed
that TINO monotherapy increases OS with a HR of 6.6
compared with untreated animals (vehicle) (Fig. 7g, 7i).
TINO was superior to RT and TMZ as single therapies and
was significantly more effective in comparison with RT plus
TMZ (Fig. 7b, 7e). Statistically significant differences in the
radio sensitizing effects of TINO versus TMZ were ob-
served in this radio- and chemo-sensitive model (Fig. 7c,
7e). The same treatments were applied to orthotopic intra-
brain xenografts originated from patient-derived GBM
stem-like cells, CSCs-5 previously transfected by luciferase.
In this cell system, untreated animals showed a biolumines-
cent positivity after about 10-20 days (16.5 ± 1.7; mean ±
SEM). RT increased DFS up to 29.5 ± 2.3 days (Fig. 8a).
Mean DFS was also significantly increased with TINO
(81.0 ± 7.4) and TMZ (62.0 ± 8.1) treatments. TMZ plus RT
showed a DFS of 82.0 ± 15.7 days whereas the TINO plus
RT combination was significantly greater at 144.0 ±
15.9 days (p < 0.0005). TINO monotherapy reduced tumor
progression on Kaplan-Meier analysis compared with un-
treated animals (Fig. 8b, 8d). TINO was superior to RT and
temozolomide as single treatments. TINO in combination
with RT further reduced tumor progression compared with
vehicle (#Fig. 8b, 8d) and either RT or TINO (Fig. 8c, 8e).
Statistically significant differences in the radio-sensitizing
effects of TINO versus TMZ in this radio- and chemo-
sensitive model were observed (Fig. 8e) suggesting that
TINO shows higher radio-sensitizing effects than TMZ.
Untreated animals showing distress signs and were sacri-
ficed after about 50 days (48.0 ± 3.6). RT increased OS,
slowing mean recurrence to 80.0 ± 4.8 days (Fig. 8f). Mean




Fig. 8 Orthotopic intra-brain injection of differentiated U251 cells. a Graphical analyses for the time of time to detection of bioluminescence which is
related to Disease Free survival (DFS) parameter: Median ± CI 95% DFS data (days) for each treatment. b Kaplan Meyer curves generated for tumor
detection in animal of control or treated with single treatments (RT, TINO and TMZ). c Kaplan Meyer curves generated for DFS data in animal treated
with RT, TINO and their combination. Comparison with standard chemo-radiotherapy consisting in the combination of RT and TMZ. d Forest plots for
the comparison of DFS with untreated animals (vehicle treated). e Forest plots for comparison of DFS in combination regimens. f Graphical analyses
for the time of overall survival (OS): median ± CI 95% OS data (days) for each treatment. g Kaplan-Meier curves generated for OS in animal of control
(Vehicle), or treated with RT, TINO and TMZ for the comparison of single treatments. h Kaplan-Meier curves generated for OS in animal treated with RT,
TINO, and their combination. Comparison with standard chemo-radiotherapy consisting in the combination of RT and TMZ. i Forest plots for the
comparison of OS with untreated animals (vehicle treated). j Forest plots for comparison of OS in combination regimens
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DFS was also significantly increased with TINO (140.0 ±
23.5) and TMZ (105.5 ± 16.5) treatments. Combination
with TMZ and RT showed a DFS of 145.0 ± 22.5 days
whereas the combination RT with TINO reached 210.0 ±
35.0 days.
Analyzing the Kaplan-Meier curves obtained plotting
the percentage of sacrificed animals in the time; we ob-
serve that TINO monotherapy increases OS with a HR
of 5.8 with respect to vehicle, compared with untreated
animals (Fig. 8g, 8i). TINO was superior to RT and TMZ
as single therapies. TINO in combination with RT fur-
ther increases OS compared with vehicle (Fig. 8g, 8i),
RT (Fig. 8h, 8j), or TINO (Fig. 8h, 8j). Statistically sig-
nificant differences in the radio-sensitizing effects of
TINO versus TMZ were also observed in this radio- and
chemo-sensitive model suggesting that TINO show
higher radio-sensitizing effects than TMZ.
Additional file 2: Tables S2 and S3 summarizes statistical
analyses of Figs. 8 and 9.
Discussion
High-grade gliomas represent the most aggressive pri-
mary brain tumors showing high resistance to classic
cytotoxic therapies. DNA damage triggers a series of sig-
naling cascades promoting cell death as well as cellular
survival, including DNA repair, cell cycle arrest, and au-
tophagy. The elevated basal and/or stressful levels of
both DNA repair and autophagy observed in tumor
cells, in contrast to normal cells, have been identified as
the most important drug-responsive programs that im-
pact the outcome of anticancer therapy. For over a dec-
ade, RT and TMZ combination therapy has been the
gold standard with clinical trial of alternatives being un-
successful [1, 3]. However, the prognosis remains poor
and some subgroups of patients, like those with MGMT
unmethylated tumors do not benefit from this regimen
[1, 8, 9] and therapeutic resistance in MGMT-
unmethylated tumors has emerged as an important clin-
ical issue. It is necessary to consider that 35 μM is the
blood peak of concentration of TMZ when this com-
pound was administered to humans [44, 45] and this
concentration was active in 5 out 12 GBM cells lines
and 2 out 7 patient-derived GBM proliferating/stem cell
lines. BDM is distributed freely in blood, with a concen-
tration at the peak ranging between 10 and 100 μg/ml
(corresponding to 28–280 μM) [46, 47] and that plasma
concentrations were approximately 100-fold higher than
in mouse brain [48]. So in vitro concentrations of BDM
are higher when compared with those observed in vivo.
In addition, T98G and SW1783 cell lines, which are
characterized by high levels of MGMT, showed a pro-
nounced resistance to TMZ (TMZ IC50 of 147.2 ±
2.1 μM and 234.6 ± 2.3 μM, respectively), whereas A172
and LN229 cell lines, which exhibit no or low MGMT
expression, had low TMZ IC50 values (14.1 ± 1.1 μM
and 14.5 ± 1.1 μM, respectively). MGMT expression sta-
tus had little effect on the activity of BDM, which dem-
onstrated an antitumor effect in TMZ-resistant GBM
cells (Fig. 1). The potential of SAHA [15, 49] and BDM
[10, 11] as a target for radio-sensitization has been previ-
ously suggested in studies with other agents in experi-
mental tumor models. In our report we test a new
therapeutic strategy to improve the therapeutic outcome
of combined radiotherapy with alkylating agents such as
BDM by using tinostamustine (EDO-S101), a first-in-
class alkylating deacetylase inhibitor (AK-DACi) mol-
ecule. This molecule fuses the DNA damaging effect of
BDM with the fully functional pan-histone deacetylase
(HDAC) inhibitor, vorinostat in a completely new chem-
ical entity [25–27, 49]. We hypothesized that tinosta-
mustine may induce radio-sensitization through
different mechanisms associated with enhanced apop-
tosis despite a RT-induced autophagy. Target cells for
these effects are both glioma cells and the glioma stem
like cells (GSCs). One of the factors underlying tumor
recurrence and poor long-term survival is, indeed, the
presence of a cancer stem-like cell population GSCs
which contribute to cancer invasion, angiogenesis, im-
mune evasion, therapeutic resistance, and may drive re-
currence [50–52]. The HDAC inhibitor vorinostat
(SAHA) has received significant attention in recent years
as an “epigenetic” drug used to treat solid tumors [53]
which down-modulate cancer stem markers inducing
differentiation of GSCs. The data presented here indicate
that TINO increases DNA damage induced after RT,
based on comet assay analyses and γH2Ax detection.
Tinostamustine was able to reduce the expression of au-
tophagy marker (LC3B and beclin1) increasing those of
p62 suggesting a shift of cell death from autophagy to
apoptosis. A further prove of this event is the reduction
of levels of Bcl2 by TINO as well as the pharmacological
inhibition of Bcl2 by AT101 (Gossypol). Reduced Bcl2
levels after co-administration of TINO to RT were trans-
lated both into an increased activity of caspase 3 (and an
increased percentage of annexin V positive apoptotic
cells. To further elucidate the role of Bcl2 in increased
radio-sensitivity we performed clonogenic experiments
on glioma cell cultures by administration of fixed 5 μM
AT101. These experiments indicated a strong radio-
sensitization of Bcl2 activity inhibition. The analyses of
dose enhancement factors, calculated for the administra-
tion of AT101 with RT indicated the stronger effect in
T98G (DRE = 1.50) and the lower effect in U251 (DRE =
1.15). A172 showed a DRE = 1.25 and U87MG a DRE =
1.28. This DRE values were compared with those ob-
served for Tinostamustine. We found that the adminis-
tration of AT101 determined similar DRE of
Tinostamustine in U87MG and A172 with an increment
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of 2.4 and 1.6% in Tinostamustine treated cells, respect-
ively. Tinostamustine was more active compared to
AT101 in U251 (+ 13.6%) whereas AT101 was more ac-
tive compared to tinostamustine in T98G (+ 20%) cells.
This could be due to differences in basal Bcl2 expression
levels observed in the different cell lines. When AT101
was administered with dual tinostamustine + RT (triple
co-administration experiments) we noted an additive ef-
fect with increments in DRE values of 4% (U87MG),
5.6% (U251), 6.7% (A172) and 30% (T98G). This suggest
that the efficacy of tinostamustine may be influenced by
Bcl2 levels also if further studies should be necessary in-
cluding Bcl2 transfection in low Bcl2 expressing glioma
cell lines. Preliminary our data suggest that the single
administration of Tinostamustine is more active in
glioma cells with lower basal levels of Bcl2 (manuscript
in preparation). Although the dose of 5.0 μM AT101,
used for this analysis, was too high to evaluate a possible
therapeutic approach, this was not a topic of the present
report also if should be considered for further studies.
Increasing evidence suggests that an inflammatory
microenvironment may promote invasion by GBM cells
[54, 55] through the activation of pathways that recruit
myeloid precursors. One interesting possible mechanism
involved in the sensitivity of GBM tumors to TINO and
TINO plus RT is the recruitment of monocytes/macro-
phages. The possible involvement of proliferating mono-
cytes is also invoked due to the presence of close
“germinal cores/cluster” dispersed in the necrotic tumor
masses. This event could have dual effects: to participate
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Fig. 9 Orthotopic intra-brain injection of patient-derived GBM stem-like cells (CSCs-5) and comparison with different treatment groups. a Graphical
analyses for the time of Time to detection of bioluminescence or DFS: Median ± CI 95% DFS data (days) for each treatment. b Kaplan-Meier curves
generated for tumor detection in animal of control or treated with single treatments (RT, TINO and TMZ). c Kaplan Meyer curves generated for DFS
data in animal treated with RT, TINO and their combination. Comparison with standard chemo-radiotherapy consisting in the combination of RT and
TMZ. d Forest plots for the comparison of DFS with untreated animals (vehicle treated). e Forest plots for comparison of DFS in combination regimens.
f Graphical analyses for the time of overall survival (OS): Median ± CI 95% OS data (days) for each treatment. g Kaplan-Meier curves generated for OS in
animal of control (Vehicle), or treated with RT, TINO, and TMZ for the comparison of single treatments. h Kaplan Meyer curves generated for OS in
animal treated with RT, TINO, and their combination. Comparison with standard chemo-radiotherapy consisting in the combination of RT and TMZ. i
Forest plots for the comparison of OS with untreated animals (vehicle treated). j Forest plots for comparison of OS in combination regimens
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in the elimination of necrotic cells (resolution) or to
mediate the awakening of quiescent stem cells (leading
to recurrence). The latter effect was not supported by
results in the orthotopic models, which demonstrated no
increase in recurrence with TINO and the TINO plus
RT combination after only 35 days of treatment (one
treatment cycle). The rate of recurrence and the survival
percentage in combination treatment were significantly
better than those observed for the standard treatment,
TMZ plus RT, providing evidence against recurrence
due to stimulation of cancer stem cells.
Conclusions
These data demonstrate that TINO is a broadly active
antitumor agent in vitro and in vivo, with potent radio-
sensitizing activity in aggressive and TMZ-resistant glio-
blastoma tumor models, supporting ongoing clinical
evaluation of this compound in combination with RT for
the treatment of post-surgery glioblastoma patients.
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